検索
Connect Biopharma Holdings Ltd
CNTBウォッチリストに追加
1.070USD
-0.145-11.93%
終値 09-23 16:00（ET）
59.62M時価総額
損失額直近12ヶ月PER
前場取引 07:02 (ET)1.080USD+0.010+0.94%
前場取引 07:02 (ET)Connect Biopharma Holdings Ltdについて 企業名
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Connect Biopharma Holdings Ltd プロフィール
企業コードCNTB
会社名Connect Biopharma Holdings Ltd
上場日Mar 19, 2021
最高経営責任者「CEO」Quart (Barry D)
従業員数62
証券種類Ordinary Share
決算期末Mar 19
本社所在地3580 Carmel Mountain Road, Suite 200
都市SAN DIEGO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号92130
電話番号18587271040
ウェブサイトhttps://www.connectbiopharm.com
企業コードCNTB
上場日Mar 19, 2021
最高経営責任者「CEO」Quart (Barry D)
Connect Biopharma Holdings Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
11.78K
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
よくある質問
Connect Biopharma Holdings Ltdの上位5名の株主は誰ですか？
Connect Biopharma Holdings Ltdの上位5名の株主は以下のとおりです。Dr. Barry D. Quart, Pharm.D.
Connect Biopharma Holdings Ltd（CNTB）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Connect Biopharma Holdings Ltdの株式を保有している機関は51社あり、保有株式の総市場価値は約29.94Mで、全体の52.97%を占めています。2025Q4と比較して、機関の持ち株は8109973.00増加しています。